Advancing Education on Biosimilars Act of 2021
Latest action · Mar 16, 2021 Referred to the Subcommittee on Health.
Progress
Where this bill reached, and when. A stage with no date was not reached; one that failed a vote and later carried shows the date it carried.
- IntroducedMar 12, 2021
- Passed HouseNot reached
- Passed SenateNot reached
- To the PresidentNot reached
- Became lawNot reached
Summary
Advancing Education on Biosimilars Act of 2021
This bill requires the Food and Drug Administration (FDA) to advance education and awareness among health care providers about biological products as appropriate, including by developing or improving continuing education programs that address the prescribing of biological products and biosimilars. (A biosimilar is a biological product that is highly similar to an FDA-approved reference biological product and has no clinically meaningful differences from that reference product.)
The FDA may also maintain and operate a website to provide educational materials about biological products.
Cosponsors 1
Members who signed on, in the order they did. All signed on Mar 12, 2021.
| Seat | Cosponsor | Signed on | |
|---|---|---|---|
| D-CA | Scott H. Peters | Original | Mar 12, 2021 |
Committees 1
Where it was sent and what each committee and subcommittee did with it, in order.
| Chamber | Committee | What it did |
|---|---|---|
| House | Energy and Commerce Committee | Referred Mar 12, 2021 |
| Health Subcommittee | Referred Mar 16, 2021 |
Actions 3
Everything that happened, newest first.
- Mar 16, 2021Referred to the Subcommittee on Health.
- Mar 12, 2021Introduced in House
- Mar 12, 2021Referred to the House Committee on Energy and Commerce.
Research
What has been written about this bill: committee reports, cost estimates, the sponsor’s authority statement, printed hearings and the Congressional Research Service’s work.
Constitutional authority
The sponsor’s statement, as printed in the Congressional Record, vol. 167, no. 47, March 12, 2021, page H1364.
Related bills 2
Companion bills and other measures the record links to this one.
| Bill | Title | Relationship | Latest action |
|---|---|---|---|
| HR 19 | Lower Costs, More Cures Act of 2021 | Related bill | Oct 19, 2021 |
| S 164 | Advancing Education on Biosimilars Act of 2021 | Identical bill | Apr 23, 2021 |
Titles 2
Every title it has carried, official and short, at each stage.
- Official Title as Introduced
- To educate health care providers and the public on biosimilar biological products, and for other purposes.
- Short Title(s) as Introduced
- Advancing Education on Biosimilars Act of 2021
Subjects
Assigned by the Library of Congress. Policy area: Health.
Text 1
Each version as it was printed, newest first.
- Mar 12, 2021Introduced in House
Everything here is as published by Congress: the summary is the Congressional Research Service's, the action wording is the clerks', and the subjects are the Library of Congress's. How far it got is read from the actions themselves, taking the most recent one of each kind, so a bill that failed a vote and later passed is shown as having passed. Records come from this bill on Congress.gov and govinfo.gov; cost estimates are the Congressional Budget Office's, and the hearings are the printed hearings GovInfo publishes, which can appear months after the hearing.